NZ241979A
(en)
*
|
1991-03-20 |
1996-01-26 |
Merck & Co Inc |
Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
|
AU5549494A
(en)
*
|
1992-11-04 |
1994-05-24 |
Sepracor, Inc. |
Methods and compositions of (+) doxazosin for the treatment of hypertension
|
NZ257993A
(en)
*
|
1992-11-04 |
1997-05-26 |
Sepracor Inc |
Use of (+)-doxazosin and medicament containing the compound
|
US5294615A
(en)
*
|
1993-04-29 |
1994-03-15 |
Abbott Laboratories |
Terazosin polymorph and pharmaceutical composition
|
US5412095A
(en)
*
|
1993-04-29 |
1995-05-02 |
Abbott Laboratories |
Terazosin monohydrochloride and processes and intermediate for its production
|
US5504207A
(en)
*
|
1994-10-18 |
1996-04-02 |
Abbott Laboratories |
Process and intermediate for the preparation of terazosin hydrochloride dihydrate
|
US5587377A
(en)
*
|
1995-10-24 |
1996-12-24 |
Invamed, Inc. |
Terazosin crystalline polymorph and pharmaceutical compositions thereof
|
EP0865280A1
(de)
*
|
1995-11-15 |
1998-09-23 |
Merck & Co., Inc. |
ALPHA 1a ADRENERGISCHE REZEPTORANTAGONISTEN
|
DE19546573A1
(de)
*
|
1995-12-13 |
1997-06-19 |
Uetikon Chemie Gmbh |
Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
|
US5952003A
(en)
*
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
US5922722A
(en)
*
|
1996-11-12 |
1999-07-13 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
IT1286789B1
(it)
*
|
1996-11-29 |
1998-07-17 |
Alfa Chem Ital |
Processo per la produzione della forma i del terazosin monocloridato anidro
|
GB9708917D0
(en)
*
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
US6376503B1
(en)
|
1997-06-18 |
2002-04-23 |
Merck & Co., Inc |
Alpha 1a adrenergic receptor antagonists
|
US6057350A
(en)
*
|
1997-06-18 |
2000-05-02 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6037354A
(en)
*
|
1997-06-18 |
2000-03-14 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6214832B1
(en)
|
1997-06-18 |
2001-04-10 |
Merck & Co., Inc. |
Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
|
US6080760A
(en)
*
|
1997-06-18 |
2000-06-27 |
Merck & Co., Inc. |
Alpha 1A adrenergic receptor antagonists
|
US6143750A
(en)
*
|
1997-06-18 |
2000-11-07 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6248888B1
(en)
|
1997-11-14 |
2001-06-19 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of terazosin hydrochloride dihydrate
|
AU5234899A
(en)
|
1998-07-30 |
2000-02-21 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
WO2000025782A1
(en)
|
1998-10-29 |
2000-05-11 |
Merck & Co., Inc. |
Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
|
US6228870B1
(en)
|
1998-11-10 |
2001-05-08 |
Merck & Co., Inc. |
Oxazolidinones useful as alpha 1a adrenoceptor antagonists
|
US6319932B1
(en)
|
1998-11-10 |
2001-11-20 |
Merck & Co., Inc. |
Oxazolidinones useful as alpha 1A adrenoceptor antagonists
|
AU1345600A
(en)
|
1998-11-12 |
2000-06-05 |
Merck & Co., Inc. |
Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
|
DE19856440C2
(de)
*
|
1998-12-08 |
2002-04-04 |
Bosch Gmbh Robert |
Übertragungsrahmen und Funkeinheit mit Übertragungsrahmen
|
DE19856441C5
(de)
*
|
1998-12-08 |
2004-11-18 |
Robert Bosch Gmbh |
Verfahren zur Übertragung von Kurznachrichten
|
US6358959B1
(en)
|
1999-01-26 |
2002-03-19 |
Merck & Co., Inc. |
Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355264A
(en)
|
1999-09-30 |
2001-04-18 |
Merck & Co Inc |
Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355263A
(en)
|
1999-09-30 |
2001-04-18 |
Merck & Co Inc |
Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355456A
(en)
|
1999-09-30 |
2001-04-25 |
Merck & Co Inc |
Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355457A
(en)
|
1999-09-30 |
2001-04-25 |
Merck & Co Inc |
Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
|
US6200573B1
(en)
|
1999-12-03 |
2001-03-13 |
Starcor Pharmaceuticals, Inc. |
Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
|
US6313172B1
(en)
|
2000-04-13 |
2001-11-06 |
Allergan Sales, Inc. |
Methods and compositions for modulating alpha adrenergic receptor activity
|
US7335803B2
(en)
|
2001-10-19 |
2008-02-26 |
Allergan, Inc. |
Methods and compositions for modulating alpha adrenergic receptor activity
|
JP2002121188A
(ja)
*
|
2000-07-18 |
2002-04-23 |
Toray Ind Inc |
ピペラジンアミド化合物の製造法およびピペラジンテトラヒドロフラン−2−カルボン酸アミド誘導体
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20020198215A1
(en)
*
|
2000-10-23 |
2002-12-26 |
Lino Tavares |
Terazosin transdermal device and methods
|
US6534542B2
(en)
|
2001-02-27 |
2003-03-18 |
Allergen Sales, Inc. |
(2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
|
US7358269B2
(en)
|
2002-05-21 |
2008-04-15 |
Allergan, Inc. |
2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
|
US7323485B2
(en)
|
2002-05-21 |
2008-01-29 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
US7276522B2
(en)
|
2002-05-21 |
2007-10-02 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
US7091232B2
(en)
|
2002-05-21 |
2006-08-15 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
CN102657664A
(zh)
|
2003-09-12 |
2012-09-12 |
阿勒根公司 |
用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物
|
US7390829B2
(en)
|
2005-06-29 |
2008-06-24 |
Allergan, Inc. |
Alpha-2 adrenergic agonists
|
US7323477B2
(en)
|
2006-02-02 |
2008-01-29 |
Allergan, Inc. |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
|
CN101547696A
(zh)
*
|
2006-08-08 |
2009-09-30 |
奥斯拜客斯制药有限公司 |
具有α肾上腺素能阻断效应的取代喹唑啉化合物的制备和应用
|
US7598417B2
(en)
|
2007-04-12 |
2009-10-06 |
Allergan, Inc. |
Substituted fluoroethyl ureas as alpha 2 adrenergic agents
|
ES2390323T3
(es)
|
2007-05-23 |
2012-11-08 |
Allergan, Inc. |
Compuestos terapéuticos de ((fenil)imidazolil)metilquinolinilo
|
JP5524047B2
(ja)
|
2007-05-23 |
2014-06-18 |
アラーガン インコーポレイテッド |
緑内障および眼圧上昇の治療用環状ラクタム類
|
US7902247B2
(en)
|
2008-01-09 |
2011-03-08 |
Allergan, Inc. |
Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
|
US7829587B2
(en)
|
2008-01-09 |
2010-11-09 |
Allergan, Inc. |
Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
|
WO2009091759A1
(en)
|
2008-01-18 |
2009-07-23 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US8809379B2
(en)
|
2008-01-18 |
2014-08-19 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US20090239918A1
(en)
*
|
2008-03-24 |
2009-09-24 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US9072727B2
(en)
|
2008-04-18 |
2015-07-07 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of degenerative disc disease
|
US8420114B2
(en)
|
2008-04-18 |
2013-04-16 |
Warsaw Orthopedic, Inc. |
Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
|
EP2280707A1
(de)
|
2008-05-05 |
2011-02-09 |
Allergan, Inc. |
Alpha2b- und alpha2c-agonisten
|
WO2009140204A2
(en)
|
2008-05-16 |
2009-11-19 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
AU2009333620A1
(en)
|
2008-12-08 |
2011-07-07 |
Allergan, Inc. |
N-(1-phenyl-2-arylethyl)-4,5-dihydro-3H-pyrrol-2-amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors
|
JP2012517433A
(ja)
|
2009-02-06 |
2012-08-02 |
アラーガン インコーポレイテッド |
アルファ2bおよび/またはアルファ2cアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物
|
EP2459542B1
(de)
|
2009-07-30 |
2014-10-29 |
Allergan, Inc. |
Substituierte N-Benzyl-4,5-Dihydrooxazol-2-Amine als selective alpha-2B/2C-Rezeptoragonisten
|
US9040532B2
(en)
|
2009-10-06 |
2015-05-26 |
Allergan, Inc. |
Alpha adrenergic receptor modulators
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
US11224572B1
(en)
*
|
2020-08-17 |
2022-01-18 |
Novitium Pharma LLC |
Stable oral liquid composition of terazosin
|